Access a PDF of the poster by clicking on the hyperlinked title below.

  • ABSTRACT 5547
    TITLE: Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): activity and safety analyses in Phase I pooled expansion cohorts.
  • ABSTRACT 5553
    TITLE: Safety findings from FORWARD II: A Phase 1b study evaluating the folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin (PLD), or pembrolizumab in patients (pts) with ovarian cancer.
    FORWARD I (GOG 3011): A randomized phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRa)-positive, platinum-resistant epithelial ovarian cancer (EOC), primary peritoneal cancer, or primary fallopian tube cancer.

For more information, please contact

You are now leaving this website. If you would like to continue, click Continue.